
Halozyme Therapeutics, Inc.
HALO
HALO: Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme utilizes a strategy that focuses on developing its own proprietary products in therapeutic areas with significant unmet medical needs, with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.
moreShow HALO Financials
Recent trades of HALO by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by HALO's directors and management
Government lobbying spending instances
-
$20,000 Jul 16, 2023 Issue: Medicare/Medicaid
-
$30,000 Apr 19, 2020 Issue: Science/Technology Health Issues Medicare/Medicaid
-
$30,000 Jan 19, 2020 Issue: Medicare/Medicaid Science/Technology Health Issues
-
$20,000 Oct 20, 2019 Issue: Medicare/Medicaid Science/Technology Health Issues
-
$20,000 Aug 08, 2006 Issue: Health Issues Pharmacy
-
$20,000 Feb 14, 2006 Issue: Health Issues Pharmacy
New patents grants
Federal grants, loans, and purchases
Followers on HALO's company Twitter account
Number of mentions of HALO in WallStreetBets Daily Discussion
Recent insights relating to HALO
Recent picks made for HALO stock on CNBC
ETFs with the largest estimated holdings in HALO
Flights by private jets registered to HALO